Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting on its ovarian cancer CAR-T therapy trial. Scheduled for November 10, 2022, at 9:00 AM EST, the presentation will be led by Dr. Robert Wenham from Moffitt Cancer Center. The trial focuses on genetically engineered T-cells targeting the follicle-stimulating hormone receptor in recurrent ovarian cancer patients. Anixa is advancing various therapeutic programs, including collaborations for COVID-19 and breast cancer vaccines.

Positive

• Anixa's CAR-T therapy trial for ovarian cancer shows potential in targeting specific cancer receptors.
• Collaboration with Moffitt Cancer Center enhances credibility and research capabilities.
• Presentation at SITC provides visibility and engagement with the oncology community.

Negative

• None.

SAN JOSE, Calif., Oct. 10, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining its ovarian cancer CAR-T therapy trial at the Society for Immunotherapy of Cancer (SITC) 37^th Annual Meeting being held November 8-12, 2022.  The presentation, titled "Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer (OVCA)," will be presented by the study's principal investigator, Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center, Anixa's collaboration partner.

Additional presentation details can be found below:

Abstract #: 672

Date/Time: November 10, 2022, 9:00 AM EST

About Anixa Biosciences, Inc.

Anixa is a clinical-stage biotechnology company with programs addressing cancer and infectious disease.  Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the M^pro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants.  The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer.  These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.  Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.  To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn and Facebook.

Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-ovarian-cancer-car-t-therapy-trial-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-301644253.html

SOURCE Anixa Biosciences, Inc.

FAQ

What is the focus of Anixa Biosciences' presentation at the SITC Annual Meeting?

Anixa Biosciences will present its ovarian cancer CAR-T therapy trial focusing on genetically engineered T-cells targeting the follicle-stimulating hormone receptor.

When is Anixa Biosciences presenting at the SITC Annual Meeting?

Anixa Biosciences is scheduled to present on November 10, 2022, at 9:00 AM EST.

Who is leading the presentation on Anixa's CAR-T therapy trial?

The presentation will be led by Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center.

What is the significance of Anixa's CAR-T therapy trial for ovarian cancer?

The trial focuses on an innovative approach to target ovarian cancer, which could potentially improve treatment options for recurrent cases.

What collaborations does Anixa Biosciences have for its therapeutic programs?

Anixa collaborates with Moffitt Cancer Center for its CAR-T therapy and with MolGenie GmbH for its COVID-19 program, along with partnerships for breast cancer vaccines.